title: The therapeutic potential of I-domain integrins.
abstract: Due to their role in processes central to cancer and autoimmune disease I-domain integrins are an attractive drug target. Both antibodies and small molecule antagonists have been discovered and tested in the clinic. Much of the effort has focused on αLβ2 antagonists. Maybe the most successful was the monoclonal antibody efalizumab, which was approved for the treatment of psoriasis but subsequently withdrawn from the market due to the occurrence of a serious adverse effect (progressive multifocal leukoencephalopathy). Other monoclonal antibodies were tested for the treatment of reperfusion injury, post-myocardial infarction, but failed to progress due to lack of efficacy. New potent small molecule inhibitors of αv integrins are promising reagents for treating fibrotic disease. Small molecule inhibitors targeting collagen-binding integrins have been discovered and future work will focus on identifying molecules selectively targeting each of the collagen receptors and identifying appropriate target diseases for future clinical studies.
authors.affiliation: Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland.
authors.forename: Marian
authors.initials: M
authors.lastname: Brennan
authors.forename: Dermot
authors.initials: D
authors.lastname: Cox
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000502:physiology; D017434:Protein Structure, Tertiary
chemical_list: D000911:Antibodies, Monoclonal; D016023:Integrins